Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 9/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14031234 | 1.00 | DRD4 (0.34) | DRD4RXRARXRBRXRGDRD2 | |
| SCHEMBL5046966 | 0.90 | — | — | |
| SCHEMBL14031274 | 0.90 | — | — | |
| SCHEMBL5043187 | 0.81 | CRHR1 (0.37) | RXRARXRBRXRGCRHR1 | |
| SCHEMBL5043789 | 0.79 | CRHR1 (0.32) | CRHR1 | |
| SCHEMBL5043790 | 0.79 | CRHR1 (0.32) | CRHR1 | |
| SCHEMBL5039792 | 0.77 | CYP2D6 (0.34) | CRHR1 | |
| SCHEMBL14031276 | 0.77 | CYP2D6 (0.34) | CRHR1 | |
| SCHEMBL14049592 | 0.77 | CYP2D6 (0.34) | CRHR1 | |
| SCHEMBL5043160 | 0.76 | CRHR1 (0.31) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197330-A1 | Heterocyclic GABAA subtype selective receptor modulators | GABRA2, GABRA1, GABRA5 | DRD4 524/4885RXRA 659/4885RXRB 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.